SynthesisFrontiers in public health2024
Global prevalence of norovirus gastroenteritis after emergence of the GII.4 Sydney 2012 variant: a systematic review and meta-analysis.
Synthesis in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disease burden of norovirus-associated diarrhea among children under 5 years old in China: a meta-analysis.BMC infectious diseases · 2025Pooled it
- Wastewater-based surveillance of norovirus GI and GII: Comparative performance of commercial and in-house RT-qPCR Assays.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Sustained persistence of blockade antibodies against emerging GII.4 and GII.17 noroviruses revealed by a 5-year community-based serological study.Frontiers in cellular and infection microbiology · 2026Article
- A red/blue bicolor lateral flow immunoassay for simultaneous detection of two enteroviruses based on duplex RT-LAMP.Frontiers in microbiology · 2026Article
- CVID Enteropathy Associated With Chronic Norovirus Infection: Background, Clinical Features, and Therapeutic Aspects.Reviews in medical virology · 2025Review
- Article
- Prevalence and Genotype Distribution of Sapovirus in China: A Systematic Review and Meta-Analysis.Global challenges (Hoboken, NJ) · 2025Review
- Vaccinia Virus Vector Bivalent Norovirus Vaccine.Viruses · 2025Article
- Emergence of norovirus GII.17[P16] in adult patients with acute gastroenteritis in Thailand during 2021-2023.PloS one · 2025Article
- Prevalence and genotype distribution of human norovirus infections in Ghana: A systematic review and meta-analysis.Environmental health insights · 2025Review
- A large-scale norovirus outbreak associated with kimchi consumption across multiple schools in a Korean city in 2024.Epidemiology and health · 2025Article
- Machine Learning and Imputation to Characterize Human Norovirus Genotype Susceptibility to Sodium Hypochlorite.Food and environmental virology · 2024Article
- Prevalence and associated factors of norovirus infections among patients with diarrhea in the Amhara national regional state, Ethiopia.BMC infectious diseases · 2024Article
- Increased circulation of GII.17 noroviruses, six European countries and the United States, 2023 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Global burden and trends of norovirus-associated diseases from 1990 to 2021 an observational trend study.Frontiers in public health · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Norovirus is widely recognized as a leading cause of both sporadic cases and outbreaks of acute gastroenteritis (AGE) across all age groups. The GII.4 Sydney 2012 variant has consistently prevailed since 2012, distinguishing itself from other variants that typically circulate for a period of 2-4 years. Objective: This review aims to systematically summarize the prevalence of norovirus gastroenteritis following emergence of the GII.4 Sydney 2012 variant. Methods: Data were collected from PubMed, Embase, Web of Science, and Cochrane databases spanning the period between January 2012 and August 2022. A meta-analysis was conducted to investigate the global prevalence and distribution patterns of norovirus gastroenteritis from 2012 to 2022. Results: The global pooled prevalence of norovirus gastroenteritis was determined to be 19.04% (16.66-21.42%) based on a comprehensive analysis of 70 studies, which included a total of 85,798 sporadic cases with acute gastroenteritis and identified 15,089 positive cases for norovirus. The prevalence rate is higher in winter than other seasons, and there are great differences among countries and age groups. The pooled attack rate of norovirus infection is estimated to be 36.89% (95% CI, 36.24-37.55%), based on a sample of 6,992 individuals who tested positive for norovirus out of a total population of 17,958 individuals exposed during outbreak events. Conclusion: The global prevalence of norovirus gastroenteritis is always high, necessitating an increased emphasis on prevention and control strategies with vaccine development for this infectious disease, particularly among the children under 5 years old and the geriatric population (individuals over 60 years old).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.